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Rapid-acting insulin analogs are increas-
ingly used during type 1 diabetic preg-
nancy. They may assist women to safely
optimize glucose control (1,2), but
little is known about their pharmacoki-
netics and reproducibility in pregnancy.
Using a unique data set of 1,300 plasma
insulin samples collected under strictly
observed experimental conditions, we
explored the relationship between as-
part pharmacokinetics and clinical and
demographic factors. We also assessed
reproducibility both within and be-
tween pregnant women using continu-
ous subcutaneous insulin infusion
(CSII).
In study 1 (ISRCTN62568875), 10
women were studied on two occasions
under sedentary conditions with pran-
dial boluses administered before stan-
dardized evening and breakfast meals
in early (12–16 weeks) and in late
(28–32 weeks) gestation (3). In study
2 (ISRCTN50385583), 12 women were
studied on two occasions in midgesta-
tion (19 and 23 weeks) (4). The boluses
were administered before standardized
evening and breakfast meals (60-g carbo-
hydrate dinner, 50-g carbohydrate break-
fast). Physical activity was encouraged
with postprandial walking (20 min after
each meal) with 50 min of brisk treadmill
walking (3.9 km/h) after breakfast (4).
Ethics approval was obtained from
Suffolk, Norfolk, and Cambridgeshire
(study 1) and Essex 2 Research ethics
committees (study 2).
Participants (n5 22) had amean age of
32 (4.5) years; diabetes duration, 18 (8.7)
years; gestational age, 22 (6.5) weeks;
BMI, 27.0 (3.3) kg/m2; and booking
HbA1c, 7.1% (1.0) (54 [10.9] mmol/mol).
Each mealtime was considered sepa-
rately so that the basic unit of study
is a time series (5-h proﬁle) of insulin con-
centration after breakfast or dinner, with
88 proﬁles from 22 women (40, study 1;
48, study 2).
Plasma insulin concentration (n 5
1,302 measurements) was measured
by an immunochemiluminometric assay
(Invitron, Monmouth, U.K.) with intra-
assay coefﬁcient of variation (CV) 4.7%
and interassay CV 7.2%–8.1%. A two-
compartment model estimated time-
to-peak plasma insulin concentration
(tmax [min]), metabolic clearance rate of
insulin (MCR [mL/kg/min]), rate of plasma
insulin accumulation (Ia [pmol/L/min]),
and postprandial plasma insulin concen-
tration (Ib [pmol/L]).
The mean time-to-peak postprandial
aspart concentration was 55 min, which
was reduced to 40 min after study 2
breakfast (Table 1). This suggests that
moderate intensity physical activity
may speed up prandial insulin absorp-
tion. There was strong evidence of
delayed aspart absorption with advanc-
ing pregnancy. The time-to-peak aspart
concentration was delayed by 1.6% per
week, meaning that absorption is ap-
proximately 50% slower at 38 weeks
compared with 8 weeks of gestation. In-
terestingly, the time-to-peak was faster
(1.1% per year) in women with longer
duration of type 1 diabetes.
The between-patient variability was
less than expected from our compara-
ble data set outside pregnancy (CV for
tmax 12% andMCR 14%), compared with
33% and 44%, respectively, outside
pregnancy (5). During pregnancy, the
within-patient variability was striking
(CV for tmax 29% and MCR 29% and
23%). The percentage of inter-occasion
variation out of total variation is high
(tmax 83% and MCR 71%), implying
most variability is occasion-speciﬁc
rather than individual-speciﬁc. This
suggests that aspart pharmacokinetics
is considerably less reproducible in
pregnancy.
In summary, our observations high-
light the day-to-day challenges of opti-
mal prandial dosing in type 1 diabetic
pregnancy. They suggest that earlier
premeal boluses are required as preg-
nancy advances and that physical activ-
ity is a potentially modiﬁable means
for speeding up insulin absorption in
pregnancy.
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Table 1—Insulin aspart pharmacokinetics in type 1 diabetic pregnancy
Factor
Aspart pharmacokinetic parameter
Time to peak tmax MCR Accumulation rate Ia Postprandial concentration Ib
Association with clinical and demographic factors*
Study 2 breakfast 0.97 0.37 0.79 0.24
Gestation (weeks) 0.76 0.16 0.13 0.12
Diabetes duration 0.68 0.20 0.12 0.10
Peak bolus rate 0.15 0.14 0.64 0.12
Total daily dose 0.23 0.38 0.52 0.11
Point estimates (accuracies) of the mean for each study and meal-time combination§
min mL/kg/min pmol/L/min pmol/L
Study 2 breakfast 40 (3.4) 0.027 (0.0025) 0.058 (0.043) 36 (14)
Study 2 dinner 55 (4.0) 0.022 (0.0025) 20.037 (0.027) 29 (11)
Study 1 breakfast 55 (4.7) 0.024 (0.0019) 20.032 (0.024) 27 (11)
Study 1 dinner 55 (4.7) 0.025 (0.0019) 20.029 (0.024) 28 (11)
Point estimates (accuracies) of the effect sizes§**
Gestation (weeks) 1.6 (0.64)% 20.62 (0.75)% 20.0032 (0.0029) 0.75 (1.1)
Diabetes duration 21.1 (0.49)% 0.68 (0.56)% 0.0021 (0.0021) 20.017 (0.80)
Peak bolus rate 0.16 (1.0)% 20.18 (1.2)% 0.011 (0.0045) 0.46 (1.6)
Total daily dose 0.31 (0.29)% 20.45 (0.25)% 20.0025 (0.0011) 20.090 (0.45)
Signiﬁcant associations are indicated in boldface type. *Estimated probability of association. Only the clinical/demographic factors for which the
probability of an association$0.5 are shown. §Accuracy is measured by posterior standard deviation (the Bayesian analog of a standard error). **For
tmax and MCR, the estimated expected percentage change is shown; for Ia and Ib, the estimated expected absolute change is shown.
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